Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients.

Beverley M ShieldsMaggie ShepherdMichelle HudsonTimothy James McDonaldKevin ColcloughJaime PetersBridget KnightChris HydeSian EllardEwan R PearsonAndrew T Hattersleynull null

Published in: Diabetes care (2018)

The biomarker screening pathway for monogenic diabetes is an effective, cheap, and easily implemented approach to systematically screening all young-onset patients. The minimum prevalence of monogenic diabetes is 3.6% of patients diagnosed at age 30 years or younger.

Keyphrases

end stage renal disease
type diabetes
newly diagnosed
ejection fraction
chronic kidney disease
cardiovascular disease
peritoneal dialysis
prognostic factors
risk factors
metabolic syndrome
skeletal muscle
patient reported outcomes
insulin resistance
clinical evaluation